Novavax has selected AGC Biologics, a contract development and manufacturing organisation (CDMO), for large-scale manufacturing of an adjuvant for its Covid-19 vaccine candidate, NVX-CoV2373.
Developed using Novavax’s recombinant protein nanoparticle technology, NVX-CoV2373 is a stable, prefusion protein designed to generate antigens obtained from the coronavirus spike (S) protein.
One component of the vaccine is Matrix-M adjuvant, meant to boost the immune response and trigger high neutralising antibody levels.
As part of the collaboration, AGC Biologics will manufacture the adjuvant component. The company will focus on process development for scaled-up production of the adjuvant to boost Novavax’s capacity to deliver doses in 2020 and